{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=108", "query": { "intervention": "Cohorting", "page": 108 }, "page_size": 10 }, "pagination": { "page": 108, "page_size": 10, "total_count": 11392, "total_pages": 1140, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=109&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohorting&page=107&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T20:40:53.370Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07613684", "title": "Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "MF-300 SAD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MF-300 Food Effect", "type": "DRUG" }, { "name": "MF-300 MAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epirium Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2024-12-20", "completion_date": "2025-10-09", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 2, "location_summary": "Marlton, New Jersey • Austin, Texas", "locations": [ { "city": "Marlton", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07613684" }, { "nct_id": "NCT02331719", "title": "Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cerebral Hemorrhage" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2014-08", "completion_date": "2017-10", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Aurora, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02331719" }, { "nct_id": "NCT07290244", "title": "Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Open Angle Glaucoma (OAG)", "NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)" ], "interventions": [ { "name": "ER-100 epigenetic therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Life Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 18, "start_date": "2026-03-02", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 4, "location_summary": "Glendale, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290244" }, { "nct_id": "NCT06449209", "title": "Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "BNT327 Dose Level 1 (DL1)", "type": "DRUG" }, { "name": "BNT327 Dose Level 2 (DL2)", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2024-08-05", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 18, "location_summary": "Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clermont", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06449209" }, { "nct_id": "NCT06605014", "title": "Somatic Dysfunction in Patients With Acute Cerebrovascular Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke, Acute", "TIA", "Reproducibility of Results", "Osteopathic Manipulation", "Health-Related Quality-of-Life" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2023-09-01", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06605014" }, { "nct_id": "NCT04445701", "title": "Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "AO-176", "type": "DRUG" }, { "name": "AO-176 + Dex", "type": "DRUG" }, { "name": "AO-176 + Dex + Bort", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arch Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-11-30", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04445701" }, { "nct_id": "NCT03287271", "title": "ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "VS-6063", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael McHale", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-02-06", "completion_date": "2025-03-12", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03287271" }, { "nct_id": "NCT03532230", "title": "Cost Effectiveness of OMT for Chronic Low Back Pain", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lumbar Radiculopathy", "Lesion of Sciatic Nerve, Left Lower Limb", "Lesion of Sciatic Nerve, Right Lower Limb", "Lumbar Spinal Stenosis", "Lumbar Spondylosis", "Lumbago With Sciatica, Left Side", "Lumbago With Sciatica, Right Side" ], "interventions": [ { "name": "Osteopathic Manipulative Treatment (OMT)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Rowan University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 146, "start_date": "2019-03-22", "completion_date": "2020-02-28", "has_results": false, "last_update_posted_date": "2020-05-04", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 3, "location_summary": "East Lansing, Michigan • Stratford, New Jersey • Voorhees Township, New Jersey", "locations": [ { "city": "East Lansing", "state": "Michigan" }, { "city": "Stratford", "state": "New Jersey" }, { "city": "Voorhees Township", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532230" }, { "nct_id": "NCT06827236", "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Breast Cancer", "Unresectable Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BNT323", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2025-04-23", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 28, "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06827236" }, { "nct_id": "NCT04631601", "title": "Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Acapatamab", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 55, "start_date": "2021-01-15", "completion_date": "2023-10-23", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-11-05T20:40:53.370Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04631601" } ] }